<DOC>
	<DOC>NCT02877758</DOC>
	<brief_summary>Tomorrowlabs has developed a revolutionary cosmeceutical formulation to rejuvenate aging skin. Tomorrowlabs is conducting this research to study whether this cosmeceutical can reduce the visible signs of cutaneous aging.</brief_summary>
	<brief_title>Investigation of a Novel Cosmeceutical to Reduce the Visible Signs of Cutaneous Aging</brief_title>
	<detailed_description>It is proposed to study a cosmeceutical formulation designed to reduce the visible signs of cutaneous aging. It is expected that daily application of the formulation may minimize wrinkles and fine lines of the face.</detailed_description>
	<criteria>Healthy volunteers who desire to improve their appearance by reducing the visible signs of cutaneous aging in the face Subjects who have undergone facial plastic surgery or aesthetic dermatology treatments to the face (such as fillers and neuromodulators) in the past 6 months Subjects with a history of collagen vascular disease, cutis laxa, connective tissue disease, psoriasis, or lupus. Subjects diagnosed with scleroderma. Subjects with a body mass index (BMI) &gt; 30. Subjects taking steroid therapy.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>cutaneous aging</keyword>
	<keyword>skin rejuvenation</keyword>
	<keyword>wrinkles</keyword>
</DOC>